Tolerability and efficacy of the trifunctional antibody removab<sup>® </sup>(anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2004-07-01
|
| Series: | Cancer Cell International |
| _version_ | 1818307164075196416 |
|---|---|
| author | Bois A du Moiseenko V Biakhov M Eiermann W Ströhlein M Makhson A Lichinitser M Pfisterer J Schmalfeldt B Sommer H Gorbounova V Burges A Wimberger P Kimmig R |
| author_facet | Bois A du Moiseenko V Biakhov M Eiermann W Ströhlein M Makhson A Lichinitser M Pfisterer J Schmalfeldt B Sommer H Gorbounova V Burges A Wimberger P Kimmig R |
| author_sort | Bois A du |
| collection | DOAJ |
| first_indexed | 2024-12-13T06:54:01Z |
| format | Article |
| id | doaj.art-c6e37561d6be41c4a8e9cb9b6dce2130 |
| institution | Directory Open Access Journal |
| issn | 1475-2867 |
| language | English |
| last_indexed | 2024-12-13T06:54:01Z |
| publishDate | 2004-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Cell International |
| spelling | doaj.art-c6e37561d6be41c4a8e9cb9b6dce21302022-12-21T23:56:04ZengBMCCancer Cell International1475-28672004-07-014Suppl 1S310.1186/1475-2867-4-S1-S3Tolerability and efficacy of the trifunctional antibody removab<sup>® </sup>(anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II studyBois A duMoiseenko VBiakhov MEiermann WStröhlein MMakhson ALichinitser MPfisterer JSchmalfeldt BSommer HGorbounova VBurges AWimberger PKimmig R |
| spellingShingle | Bois A du Moiseenko V Biakhov M Eiermann W Ströhlein M Makhson A Lichinitser M Pfisterer J Schmalfeldt B Sommer H Gorbounova V Burges A Wimberger P Kimmig R Tolerability and efficacy of the trifunctional antibody removab<sup>® </sup>(anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study Cancer Cell International |
| title | Tolerability and efficacy of the trifunctional antibody removab<sup>® </sup>(anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study |
| title_full | Tolerability and efficacy of the trifunctional antibody removab<sup>® </sup>(anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study |
| title_fullStr | Tolerability and efficacy of the trifunctional antibody removab<sup>® </sup>(anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study |
| title_full_unstemmed | Tolerability and efficacy of the trifunctional antibody removab<sup>® </sup>(anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study |
| title_short | Tolerability and efficacy of the trifunctional antibody removab<sup>® </sup>(anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study |
| title_sort | tolerability and efficacy of the trifunctional antibody removab sup r sup anti epcam x anti cd3 in patients with malignant ascites due to ovarian cancer results of a phase i ii study |
| work_keys_str_mv | AT boisadu tolerabilityandefficacyofthetrifunctionalantibodyremovabsupsupantiepcamxanticd3inpatientswithmalignantascitesduetoovariancancerresultsofaphaseiiistudy AT moiseenkov tolerabilityandefficacyofthetrifunctionalantibodyremovabsupsupantiepcamxanticd3inpatientswithmalignantascitesduetoovariancancerresultsofaphaseiiistudy AT biakhovm tolerabilityandefficacyofthetrifunctionalantibodyremovabsupsupantiepcamxanticd3inpatientswithmalignantascitesduetoovariancancerresultsofaphaseiiistudy AT eiermannw tolerabilityandefficacyofthetrifunctionalantibodyremovabsupsupantiepcamxanticd3inpatientswithmalignantascitesduetoovariancancerresultsofaphaseiiistudy AT strohleinm tolerabilityandefficacyofthetrifunctionalantibodyremovabsupsupantiepcamxanticd3inpatientswithmalignantascitesduetoovariancancerresultsofaphaseiiistudy AT makhsona tolerabilityandefficacyofthetrifunctionalantibodyremovabsupsupantiepcamxanticd3inpatientswithmalignantascitesduetoovariancancerresultsofaphaseiiistudy AT lichinitserm tolerabilityandefficacyofthetrifunctionalantibodyremovabsupsupantiepcamxanticd3inpatientswithmalignantascitesduetoovariancancerresultsofaphaseiiistudy AT pfistererj tolerabilityandefficacyofthetrifunctionalantibodyremovabsupsupantiepcamxanticd3inpatientswithmalignantascitesduetoovariancancerresultsofaphaseiiistudy AT schmalfeldtb tolerabilityandefficacyofthetrifunctionalantibodyremovabsupsupantiepcamxanticd3inpatientswithmalignantascitesduetoovariancancerresultsofaphaseiiistudy AT sommerh tolerabilityandefficacyofthetrifunctionalantibodyremovabsupsupantiepcamxanticd3inpatientswithmalignantascitesduetoovariancancerresultsofaphaseiiistudy AT gorbounovav tolerabilityandefficacyofthetrifunctionalantibodyremovabsupsupantiepcamxanticd3inpatientswithmalignantascitesduetoovariancancerresultsofaphaseiiistudy AT burgesa tolerabilityandefficacyofthetrifunctionalantibodyremovabsupsupantiepcamxanticd3inpatientswithmalignantascitesduetoovariancancerresultsofaphaseiiistudy AT wimbergerp tolerabilityandefficacyofthetrifunctionalantibodyremovabsupsupantiepcamxanticd3inpatientswithmalignantascitesduetoovariancancerresultsofaphaseiiistudy AT kimmigr tolerabilityandefficacyofthetrifunctionalantibodyremovabsupsupantiepcamxanticd3inpatientswithmalignantascitesduetoovariancancerresultsofaphaseiiistudy |